A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Number of patients with hair regrowth (complete, partial, or no regrowth)
研究概览
简要总结
Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. The two agents have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.
详细描述
Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. Topical prostaglandins like latanoprost have also been used for this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. However, the two agents i.e. topical corticosteroids and topical latanoprost have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 99 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Cases of AA involving scalp and beard area, having 5 or less patches in all, involving less than 40% area
- •Stable disease without appearance of new patch or increase in size of existing patch for at least 15 days
排除标准
- •• Pregnant and lactating women
- •Patients on topical treatment for alopecia in the past fifteen days or on systemic treatment for alopecia in the past one month
- •Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis)
- •Any other coexisting hair disorder (viz., trichotillomania, androgenetic alopecia, telogen effluvium)
- •Extensive disease i.e. >5 patches of AA or area involving >40% area / alopecia totalis/ alopecia universalis/ ophiasis
研究组 & 干预措施
Topical latanoprost
Topical latanoprost 0.005%
干预措施: Topical latanoprost 0.005% (Drug)
Topical betamethasone
Topical betamethasone 0.05%
干预措施: Topical betamethasone 0.05% (Drug)
结局指标
主要结局
Number of patients with hair regrowth (complete, partial, or no regrowth)
时间窗: 4 months
Response to the treatment in terms of hair regrowth will be assessed. The reduction in the area affected by alopecia areata will be assessed for each patient
次要结局
- Number of patients suffering from adverse effects(4 months)
研究者
Sonali Bhat
Dr
Post Graduate Institute of Medical Education and Research, Chandigarh